A large analysis suggests that a multivariable risk assessment tool, called Stockholm3, can detect substantially more ...

(HealthDay News) — Stockholm3, which combines prostate-specific antigen (PSA), plasma protein biomarkers, polygenic risk, and clinical factors offers greater clinical net benefit for detecting ...

A previous study demonstrated that power against the (unobserved) true effect for the primary end point (PEP) of most phase III oncology trials is low, suggesting an increased risk of false-negative ...

In this randomized screening trial, the multivariable Stockholm3 test provided greater clinical net benefit and substantially ...

When model-based multivariable control made its debut in the 1980s, it was expected that process models, once acquired through a plant step test, would be durable and long lived. However, this ...